Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

340 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A multigene circulating biomarker to predict the lack of FOLFIRINOX response after a single cycle in patients with pancreatic ductal adenocarcinoma.
van Eijck CWF, de Koning W, van der Sijde F, Moskie M, Groot Koerkamp B, Homs MYV, van der Burg SH, van Eijck CHJ, Mustafa DAM. van Eijck CWF, et al. Among authors: van der sijde f, van der burg sh, van eijck chj. Eur J Cancer. 2023 Mar;181:119-134. doi: 10.1016/j.ejca.2022.12.024. Epub 2022 Dec 28. Eur J Cancer. 2023. PMID: 36652890 Free article.
Enhanced antitumour immunity following neoadjuvant chemoradiotherapy mediates a favourable prognosis in women with resected pancreatic cancer.
van Eijck CWF, Mustafa DAM, Vadgama D, de Miranda NFCC, Groot Koerkamp B, van Tienhoven G, van der Burg SH, Malats N, van Eijck CHJ; Dutch Pancreatic Cancer Group (DPCG). van Eijck CWF, et al. Among authors: van der burg sh. Gut. 2024 Jan 5;73(2):311-324. doi: 10.1136/gutjnl-2023-330480. Gut. 2024. PMID: 37709493 Free PMC article.
Neoantigen-directed therapeutics in the clinic: where are we?
Lybaert L, Thielemans K, Feldman SA, van der Burg SH, Bogaert C, Ott PA. Lybaert L, et al. Among authors: van der burg sh. Trends Cancer. 2023 Jun;9(6):503-519. doi: 10.1016/j.trecan.2023.02.004. Epub 2023 Apr 11. Trends Cancer. 2023. PMID: 37055237 Free PMC article. Review.
The MHC-E peptide ligands for checkpoint CD94/NKG2A are governed by inflammatory signals, whereas LILRB1/2 receptors are peptide indifferent.
Middelburg J, Ghaffari S, Schoufour TAW, Sluijter M, Schaap G, Göynük B, Sala BM, Al-Tamimi L, Scheeren F, Franken KLMC, Akkermans JJLL, Cabukusta B, Joosten SA, Derksen I, Neefjes J, van der Burg SH, Achour A, Wijdeven RHM, Weidanz J, van Hall T. Middelburg J, et al. Among authors: van der burg sh. Cell Rep. 2023 Dec 26;42(12):113516. doi: 10.1016/j.celrep.2023.113516. Epub 2023 Dec 3. Cell Rep. 2023. PMID: 38048225 Free article.
Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacy.
van Elsas MJ, Middelburg J, Labrie C, Roelands J, Schaap G, Sluijter M, Tonea R, Ovcinnikovs V, Lloyd K, Schuurman J, Riesenfeld SJ, Gajewski TF, de Miranda NFCC, van Hall T, van der Burg SH. van Elsas MJ, et al. Among authors: van der burg sh. Cancer Cell. 2024 May 16:S1535-6108(24)00135-1. doi: 10.1016/j.ccell.2024.04.011. Online ahead of print. Cancer Cell. 2024. PMID: 38759656 Free article.
CD4+ T cells produce IFN-I to license cDC1s for induction of cytotoxic T-cell activity in human tumors.
Lei X, de Groot DC, Welters MJP, de Wit T, Schrama E, van Eenennaam H, Santegoets SJ, Oosenbrug T, van der Veen A, Vos JL, Zuur CL, de Miranda NFCC, Jacobs H, van der Burg SH, Borst J, Xiao Y. Lei X, et al. Among authors: van der burg sh. Cell Mol Immunol. 2024 Apr;21(4):374-392. doi: 10.1038/s41423-024-01133-1. Epub 2024 Feb 21. Cell Mol Immunol. 2024. PMID: 38383773 Free PMC article.
Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell-Based Immunotherapies.
Groeneveldt C, Kinderman P, Griffioen L, Rensing O, Labrie C, van den Wollenberg DJM, Hoeben RC, Coffey M, Loghmani H, Verdegaal EME, Welters MJP, van der Burg SH, van Hall T, van Montfoort N. Groeneveldt C, et al. Among authors: van der burg sh. Cancer Immunol Res. 2024 Mar 4;12(3):334-349. doi: 10.1158/2326-6066.CIR-23-0480. Cancer Immunol Res. 2024. PMID: 38194598 Free PMC article.
T-cell stimulating vaccines empower CD3 bispecific antibody therapy in solid tumors.
Middelburg J, Sluijter M, Schaap G, Göynük B, Lloyd K, Ovcinnikovs V, Zom GG, Marijnissen RJ, Groeneveldt C, Griffioen L, Sandker GGW, Heskamp S, van der Burg SH, Arakelian T, Ossendorp F, Arens R, Schuurman J, Kemper K, van Hall T. Middelburg J, et al. Among authors: van der burg sh. Nat Commun. 2024 Jan 2;15(1):48. doi: 10.1038/s41467-023-44308-6. Nat Commun. 2024. PMID: 38167722 Free PMC article.
Delayed vaccine-induced CD8+ T cell expansion by topoisomerase I inhibition mediates enhanced CD70-dependent tumor eradication.
van der Sluis TC, van Haften FJ, van Duikeren S, Pardieck IN, de Graaf JF, Vleeshouwers W, van der Maaden K, Melief CJM, van der Burg SH, Arens R. van der Sluis TC, et al. Among authors: van der burg sh. J Immunother Cancer. 2023 Nov 29;11(11):e007158. doi: 10.1136/jitc-2023-007158. J Immunother Cancer. 2023. PMID: 38030302 Free PMC article.
Timed adoptive T cell transfer during chemotherapy in patients with recurrent platinum-sensitive epithelial ovarian cancer.
Verdegaal EME, Santegoets SJ, Welters MJP, de Bruin L, Visser M, van der Minne CE, de Kok PM, Loof NM, Boekestijn S, Roozen I, Westra IM, Meij P, Van der Burg SH, Kroep JR. Verdegaal EME, et al. Among authors: van der burg sh. J Immunother Cancer. 2023 Nov;11(11):e007697. doi: 10.1136/jitc-2023-007697. J Immunother Cancer. 2023. PMID: 37949617 Free PMC article.
340 results